Analyst Price Targets — AZN
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| December 10, 2025 11:14 am | — | HSBC | $216.00 | $179.64 | TheFly | AstraZeneca price target raised to $108 from $95 at HSBC |
| December 3, 2025 11:30 am | — | Morgan Stanley | $206.00 | $180.34 | TheFly | AstraZeneca price target raised to $103 from $93 at Morgan Stanley |
| July 9, 2025 7:38 pm | Luisa Hector | Berenberg Bank | $194.00 | $141.64 | TheFly | AstraZeneca price target raised to $97 from $93 at Berenberg |
| November 13, 2024 1:13 pm | Etzer Darout | BMO Capital | $176.00 | $162.38 | StreetInsider | AstraZeneca (AZN) PT Lowered to $88 at BMO Capital |
| September 11, 2024 8:18 am | Etzer Darout | BMO Capital | $178.00 | $159.88 | StreetInsider | BMO Capital Reiterates Outperform Rating on AstraZeneca (AZN) |
| May 30, 2024 7:07 am | John Eade | Argus Research | $170.00 | $153.68 | StreetInsider | AstraZeneca (AZN) PT Raised to $85 at Argus |
| May 28, 2024 9:20 am | Etzer Darout | BMO Capital | $164.00 | $153.48 | StreetInsider | BMO Capital Reiterates Outperform Rating on AstraZeneca (AZN) |
| July 12, 2023 8:44 am | Andrew Berens | Leerink Partners | $158.00 | $129.72 | Benzinga | These 3 Health Care Stocks Delivering High-Dividend Yields Are Recommended By Wall Street's Most Accurate Analysts |
| January 5, 2023 7:01 am | — | BMO Capital | $164.00 | $139.00 | Benzinga | BMO Capital Initiates Coverage On AstraZeneca with Outperform Rating, Announces Price Target of $82 |
| November 11, 2022 3:58 am | — | Leerink Partners | $156.00 | $130.18 | Benzinga | SVB Leerink Maintains Outperform on AstraZeneca, Raises Price Target to $78 |
Latest News for AZN
AZN's Ultomiris hits key goal in IgAN study, showing early proteinuria reduction as it eyes accelerated approval in major markets.
AstraZeneca's CEO told daily Handelsblatt on Tuesday that Germany risks missing out on new drugs that the Anglo-Swedish drugmaker plans to launch if the nation sticks with plans to keep spending on pharmaceuticals in check.
A third consecutive phase III success for AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) tozorakimab in chronic obstructive pulmonary disease (COPD) has reinforced Citi's conviction in the drug's blockbuster potential, though the bank's analysts flagged a minor but notable change in tone from the company's own announcement. The MIRANDA trial tested a higher-dose, fortnightly regimen of the interleukin-33 (IL-33) inhibitor.
AstraZeneca PLC's (LSE:AZN, NASDAQ:AZN) Ultomiris has met its primary endpoint in a phase III trial targeting immunoglobulin A nephropathy (IgAN), a rare...
AstraZeneca PLC's (LSE:AZN, NASDAQ:AZN) Ultomiris has met its primary endpoint in a phase III trial targeting immunoglobulin A nephropathy (IgAN), a rare inflammatory kidney disease that can progress to kidney failure. The results showed a statistically significant reduction in proteinuria, the presence of excess protein in urine that indicates kidney damage.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
Senate Trading Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.